iShares MSCI Canada (TSX) vs Cassava Sciences Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.37, while Cassava Sciences Inc trades at $1.1 (market cap $53.14M). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EWC | FLNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $4.64 |
52-Week Low | $45.86 | $1.09 |
Market Cap | — | $53.14M |
Enterprise Value | — | -$33.43M |
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.32, up 0.24% today, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The stock shows strong support at $59 and resistance at $60. Recent corporate actions include a dividend scheduled for June 2026, while financial ratios are unavailable in the current data.
The outlook for EWC is mixed, with technical strength offset by overbought conditions. Investment opportunities hinge on sustained bullish momentum above $60, but risks include potential pullbacks from current highs and reliance on broader market trends given limited fundamental data.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Trailing returns across standard periods
Latest headlines on both assets
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →